Pharmafile

JANUARY 25, 2023

US-based pharmaceutical company, Eli Lilly and Company, has announced plans to invest $450m in its manufacturing facilities at Research Triangle Park in North Carolina, US. The facility is expected to become operational in 2027 and will create over 100 new jobs for manufacturing personnel. read more

Packaging 52

Packaging Diabetes Pharmaceutical Companies Pharmaceutical Companies 52

European Pharmaceutical Review

JUNE 26, 2024

[the new facility will double] the combined square footage of all three of [Novo Nordisk]’s existing facilities in North Carolina” Overall, the expansion will support Novo Nordisk’s ability to produce injectable treatments for obesity and other chronic diseases such as diabetes. This is compared to the company’s $3.9 (DKK

Diabetes 104

Diabetes Pharmaceutical Companies Pharmaceutical Companies 104

Pharmaceutical Technology

JANUARY 10, 2023

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).

Biosimilars 52

Biosimilars Labelling Diabetes Compounding 52